publication date: Jul. 17, 2015
20150717 - Jul. 17, 2015
ISSUE 27 – JULY 17, 2015PDF

MD Anderson Faculty White Paper Calls for Executive Pay Freeze, Elimination of “Two-Class System”

 

MD Anderson Cancer Center’s faculty has asked the UT System to freeze the salaries of Ronald DePinho and members of his executive team until they reach a level of parity with faculty salaries, according to a white paper presented to UT System Chancellor Bill McRaven June 14.

The white paper—authored by the Executive Committee of the Faculty Senate and distributed confidentially to the faculty July 10—is arguably the most comprehensive representation of the faculty’s cumulative dissatisfaction with DePinho and his administration’s performance and handling of personnel matters over the past three years.

 

Iressa Returns to U.S. Market— Now with Companion Diagnostic

FDA approved Iressa (gefitinib) for patients with metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.

The drug is being approved concurrently with the therascreen EGFR RGQ PCR Kit as a companion diagnostic.

    NCCS: Covering End-of-Life Planning is a Step Toward Delivering Patient-Centered Care

    Last week, the Centers for Medicare & Medicaid Services announced plans to support Medicare beneficiaries by reimbursing doctors for advance care planning beginning in January 2016.

    The proposed codes would reimburse for discussions about an individual’s wishes, should he or she becomes too ill to make decisions, and for the completion of an advance directive.

    Funding Opportunity

    DoD Taking Applications for $75,000 Horizon Grant

    The Department of Defense is taking applications for its Horizon Award, which offers up to $75,000 in funding to support junior-level scientists to conduct impactful research with the mentorship of an experienced cancer researcher.

    The award is for principal investigators, both pre-doctoral candidates and postdoctoral fellows are eligible, and mentors that have a strong record of funding and publications. The PI and mentor must be from the same organization.

       In Brief

      • Georgetown Lombardi and John Theurer Cancer Center to form research consortium

      • City of Hope establishes professorship with $1.5 million grant

      • Maryann Roefaro named co-chair of COA administrator network

      • Synexus opens three clinical trial research centers in Eastern Europe

      • ACT for NIH appoints seven members to its advisory committee

      Drugs and Targets

      • EU approves Imbruvica in Waldenstrom’s macroglobulinemia

      • FDA grants orphan drug designation to ImMucin in multiple myeloma

      • Cleave Biosciences’s CB-5083 receives FDA orphan drug designation

      • FDA grants fast track designation to Toca 511 and Toca FC

      • FDA grants priority review to MM-398 in pancreatic cancer

      • Eli Lilly and Immunocore launch clinical trial collaboration

      Copyright (c) 2019 The Cancer Letter Inc.